Dabrafenib
About
Therapy type: Targeted therapy
Therapy strategy: B-RAF inhibition
Mappings
NCI Thesaurus: Dabrafenib (coding:ncit:C82386)
RxNorm: dabrafenib (coding:rxcui:1424911, coding:omop:43532299)
SNOMED: Dabrafenib (coding:sctid:703641001, coding:omop:45766476)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) HC (1) | BRAF p.V600E | Melanoma | Dabrafenib | |
| FDA (4) | BRAF p.V600E | Melanoma | Dabrafenib, Trametinib | |
| FDA (4) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| FDA (2) HC (2) | BRAF p.V600E | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| FDA (2) | BRAF p.V600E | Anaplastic Thyroid Cancer | Dabrafenib, Trametinib | |
| FDA (2) | BRAF p.V600E | Any solid tumor | Dabrafenib, Trametinib | |
| FDA (2) HC (2) | BRAF p.V600E | Low-Grade Glioma, NOS | Dabrafenib, Trametinib | |
| HC (2) | BRAF p.V600E | High-Grade Glioma, NOS | Dabrafenib, Trametinib | |
| HC (1) | BRAF p.V600K | Melanoma | Dabrafenib |